Affinity illudofulvene conjugates
AssigneeAF Chemicals, LLC
InventorMichael Kelner
Life of this patent
Estimating the term…
Abstract
In an embodiment of the invention, a composition for treating a cell population comprises a medicant. The medicant moiety can be an illudofulvene analog. In an embodiment of the invention, a composition for treating a cell population comprises an Affinity Medicant Conjugate (AMC). The affinity moiety can be an antibody, an antibody fragment, a receptor protein, a peptidic growth factor, an anti-angiogenic protein, a specific binding peptide, protease cleavable peptide, a glycopeptide, a peptide, a peptidic toxin, a protein toxin and an oligonucleotide. The affinity moiety can be covalently bound to the medicant via a linker.
Claims20
A compound of the formula:
- or a pharmaceutically acceptable salt thereof, where R1 and R2 each independently represent —H, -, —OH, —OCH3, —OC(═O)CH3—CH3, —CH2—CH3, —CH—(CH3)2, —C(CH3)3, —CH2—CH2—CH3, —CH2—CH—(CH3)2, —CH—C—(CH3)3, —C(═O)CH3, —CH2OH, and —(C1-C4) alkyl.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof, where R1 represents —H, -, —OH, —OCH3, —OC(═O)CH3—CH3, —CH2—CH3, —CH—(CH3)2, —C(CH3)3, —CH2—CH2—CH3, —CH2—CH—(CH3)2, —CH—C—(CH3)3, C(═O)CH3, CH2OH, and (C1-C4) alkyl.
A compound of the formula:
- or a pharmaceutically acceptable salt thereof, where R1 represents —H, -, —OH, —OCH3, —OC(═O)CH3—CH3, —CH2—CH3, —CH—(CH3)2, —C(CH3)3, —CH2—CH2—CH3, —CH2—CH—(CH3)2, —CH—C—(CH3)3, C(═O) CH3, CH2OH, and (C1-C4) alkyl.
Dependencies are inferred from the claim text.